Ara
Toplam kayıt 19, listelenen: 1-10
Physicians' Biological Drug Preference in Patients With Rheumatoid Arthritis and Spondyloarthritis With a History of Malignancy: Perspectives From the Treasure Database
(NLM (Medline), 2022)
OBJECTIVE: Because of concerns about malignancy risks, using biological disease-modifying antirheumatic drugs (bDMARDs) in patients with a history of malignancy remains a challenging issue in rheumatology practice. This ...
Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic
(Turkiye Klinikleri, 2021)
Background/aim: To evaluate treatment adherence and predictors of drug discontinuation among patients with inflammatory arthritis receiving bDMARDs within the first 100 days after the announcement of the COVID-19 pandemic. ...
UVEITIS RELATED FACTORS IN PATIENTS WITH SPONDYLOARTHRITIS
(Bmj Publishing Group, 2019)
[No Abstract Available]
Are There Any Clues to Predict Bamboo Spine in Axial Spondyloarthritis?
(Wiley, 2020)
[No Abstract Available]
Short Term Efficacy of Tumor Necrosis Factor Inhibitors in Patients with non-radiographic Axial Spondylarthritis and ankylosing Spondylitis; Results from Turkbio Registry.
(Wiley-Blackwell, 2014)
[No Abstract Available]
Psoriasis Symptom Inventory (PSI) as a patient-reported outcome in mild psoriasis: Real life data from a large psoriatic arthritis registry
(Aves, 2020)
Objective: Our aim is to test the validity of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome, to assess the psoriasis severity within the scope of rheumatology. Methods: Within the PsA international ...
Biological and targeted-synthetic disease-modifying antirheumatic drugs with concomitant methotrexate or leflunomide in rheumatoid arthritis: Real-life TReasure prospective data
(Clinical and Experimental Rheumatology S.A.S., 2021)
Objective To determine the real-life efficacy, safety, and drug-retention rates of leflunomide (LEF) or methotrexate (MTX) as a synthetic DMARD used in combination with biological DMARDs for rheumatoid arthritis (RA). ...
Methodology of a new inflammatory arthritis registry: TReasure
(Tubitak Scientific & Technical Research Council Turkey, 2018)
Background/aim: The TReasure registry, created in 2017, is an observational multicenter cohort that includes inflammatory arthritis patients. This article reviews the methodology and objectives of the TReasure registry ...
Leflunomide as a Concomitant DMARD Choice for the Biological Treatment Era of Rheumatoid Arthritis
(Wiley, 2018)
[No Abstract Available]
The Psoriatic Arthritis Registry of Turkey: results of a multicentre registry on 1081 patients
(Oxford Univ Press, 2017)
Objective. The aim was to assess the characteristics of PsA, find out how well the disease is controlled in real life, demonstrate the treatments and identify the unmet needs. Methods. The PsA registry of Turkey is a ...